Welcome to our dedicated page for Semler Scientific news (Ticker: SMLR), a resource for investors and traders seeking the latest updates and insights on Semler Scientific stock.
Semler Scientific, Inc. (Nasdaq: SMLR) is an innovative medical risk-assessment company focused on developing, manufacturing, and marketing diagnostic and testing products that enhance patient care while bridging the gap between the cost of care and its compensation. Listed on Nasdaq since February 26, 2014, Semler operates primarily in the United States, offering proprietary technology solutions that improve clinical effectiveness and efficiency for healthcare providers, insurance plans, and risk assessment groups.
Semler's flagship product, QuantaFlo®, is a rapid, in-office test for measuring arterial blood flow in the extremities. This four-minute test aids in diagnosing peripheral arterial disease (PAD) and heart dysfunction (HD). QuantaFlo® is FDA-cleared and is employed by healthcare providers to evaluate patients' risks of mortality and major adverse cardiovascular events (MACE).
Beyond QuantaFlo®, Semler Scientific has made strategic alliances and investments to expand its product portfolio. The company has an exclusive marketing and distribution agreement with Mellitus Health, Inc. for Insulin Insights™, an FDA-cleared software product that recommends optimal insulin dosing for diabetic patients. Additionally, Semler holds minority investments in Mellitus, Monarch Medical Technologies LLC (developer of EndoTool® for inpatient glycemic management), and SYNAPS Dx.
In the latest financial results for Q3 2023, Semler reported consistent growth in quarterly revenue and pre-tax net income, predominantly from QuantaFlo® sales. The company continues to focus on expanding its business into heart dysfunction diagnosis.
Semler has also recently adopted Bitcoin as its primary treasury reserve asset, reflecting a strategic move to leverage the digital currency for long-term value and as a hedge against inflation. As of June 6, 2024, the company holds 828 bitcoins, underscoring its commitment to this innovative investment strategy.
More detailed information about Semler Scientific, its products, and investment strategies can be found on their website.
Semler Scientific, Inc. (SMLR) announced it will report its financial results for the second quarter and first half of 2021 on August 2, 2021, after U.S. markets close. The conference call will be hosted by CEO Doug Murphy-Chutorian at 4:30 PM ET, alongside senior finance and marketing executives. Semler focuses on technology solutions to enhance healthcare efficiency, having launched QuantaFlo®, a point-of-care test for diagnosing peripheral arterial disease. This test helps evaluate patient risk for heart attacks and strokes, aligning with Semler's mission to support better patient care.
Semler Scientific, Inc. (OTCQB: SMLR), based in Santa Clara, California, announced that CEO Doug Murphy-Chutorian and CMO Dennis Rosenberg will present an overview at the Raymond James Human Health Innovation Conference on June 22, 2021, at 12:00 pm ET. A live webcast of the presentation will be available on the company's website under "Events and Presentations". Semler focuses on technology solutions that enhance healthcare efficiency, including its FDA-cleared product, QuantaFlo®, designed for diagnosing peripheral arterial disease.
Semler Scientific (SMLR) reported a strong Q1 2021 with revenues of $13.2 million, up 40% from Q1 2020's $9.4 million. The company achieved a 74% increase in pre-tax net income to $6.0 million, translating to $0.73 per basic share. Cash reserves rose to $26.5 million, marking a substantial $15.3 million increase. Future growth is anticipated as Semler enters a distribution agreement worth $2.0 million for product inventory. The company aims to outpace expense growth while maintaining profitability.
Semler Scientific, Inc. (OTCQB: SMLR) announced it will report its first-quarter financial results for 2021 on May 3, 2021, after market close. A conference call will be hosted by CEO Doug Murphy-Chutorian at 4:30 PM ET the same day, alongside senior financial executives. Semler focuses on technology solutions to enhance healthcare provider efficiency and has a history of FDA-cleared products like QuantaFlo®, which helps assess cardiovascular risks. This upcoming announcement may provide insights into the company’s financial health and future outlook.
Semler Scientific, Inc. (OTCQB: SMLR) announced that CEO Doug Murphy-Chutorian and CMO Dennis Rosenberg will present at the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 4:30 pm ET. They will also engage in one-on-one calls with investors. A live webcast will be accessible under the "Events and Presentations" section of the Semler Scientific website. The presentation will be archived for 90 days.
Semler specializes in technology solutions for healthcare providers, focusing on chronic disease evaluation and management, including its FDA-cleared product QuantaFlo®.
Semler Scientific (SMLR) reported strong financial results for the year ended December 31, 2020. Revenues rose to $38.6 million, reflecting an 18% increase from $32.8 million in 2019. Pre-tax net income surged 54% to $16.5 million with a 43% margin. However, net income fell 7% to $14.0 million due to a prior year's tax benefit. The company’s cash position improved significantly, reaching $22.1 million. Looking to 2021, Semler anticipates continued profitability amid challenges posed by COVID-19 regulations.
Semler Scientific, Inc. (SMLR) announced its participation in the H.C. Wainwright Global Life Sciences Conference. CEO Doug Murphy-Chutorian and CMO Dennis Rosenberg will present a company overview on March 9, 2021, accessible on-demand at semlerscientific.com/hcwr-global. Additionally, management will engage in one-on-one investor calls on March 10. Semler specializes in technology solutions for improving clinical effectiveness, focusing on chronic disease evaluation.
Semler Scientific, Inc. (OTCQB: SMLR) announced it will release financial results for Q4 and the full year ended December 31, 2020, on March 1, 2021, after U.S. markets close. CEO Doug Murphy-Chutorian will host a conference call at 4:30 PM ET the same day, joined by senior finance officials. Participants are encouraged to pre-register for immediate access to the call. Semler Scientific focuses on technology solutions that enhance healthcare provider effectiveness and efficiency and has received FDA clearance for its flagship product QuantaFlo®, aiding in diagnosing peripheral arterial disease.
Semler Scientific, Inc. (SMLR), based in San Jose, California, announced participation in several upcoming virtual investor conferences in September 2020. The events include the 5th Annual Colliers Securities Conference on September 10, the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 15, and the 4th Annual Best Ideas Growth (BIG4) Conference on September 17. The company focuses on improving healthcare efficiency with technology solutions, notably its QuantaFlo® product, which assists in diagnosing peripheral arterial disease.
Semler Scientific, Inc. (OTCQB: SMLR) announced the appointment of Daniel Messina to its Board of Directors effective August 13, 2020. With nearly 40 years of healthcare and technology experience, Messina brings valuable insights to the company. His prior roles include co-founder of HandsFree Health and leadership positions at West Corporation and Aetna Health. The Board now comprises four members, aiming to enhance strategic growth and the development of proprietary products for chronic disease evaluation.
FAQ
What is the current stock price of Semler Scientific (SMLR)?
What is the market cap of Semler Scientific (SMLR)?
What does Semler Scientific, Inc. do?
What is QuantaFlo®?
When did Semler Scientific go public?
What recent achievements has Semler Scientific made?
What is Insulin Insights™?
How is Semler Scientific involved with Bitcoin?
Who are Semler Scientific’s primary customers?
Where is Semler Scientific headquartered?
What other companies is Semler Scientific invested in?
What is the financial outlook for Semler Scientific?
